The Drug Information Association (DIA), a US-based advisory organisation, and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) announced on Thursday the DIA-MHRA Global Summit: Global Collaboration for Safer and Smarter Health Innovation.

This event is scheduled to take place in London on 16-17 November 2026 during London Life Sciences Week and will bring together global leaders from across the life sciences ecosystem to advance collaboration, accelerate innovation and improve patient access to healthcare.

The event is anchored in three foundational commitments: Patient Safety & Public Health Impact -- advancing evidence-based regulatory frameworks that protect patients and support robust pharmacovigilance across global markets; Scientific Innovation & Regulatory Modernisation -- enabling adaptive, science-driven approaches to drug development and regulatory review that keep pace with the next generation of therapies; and Global Collaboration & Knowledge Exchange -- building a more connected and responsive health innovation ecosystem through sustained dialogue between regulators, industry, academia, and patient advocates.

Over two days, the programme will feature keynote addresses, panel discussions and case studies exploring next-generation medicines, including cell, gene and mRNA therapies. Sessions will also explore the future of clinical research, real-world evidence, AI-enabled healthcare, international regulatory alignment, biomedical investment and innovation, and new approaches to accelerating patient access, particularly for those living with rare diseases.